Romatoid Artrit Tedavisinde Uygulanan Güncel Yaklaşımlar

Yıl 2019, , 197 - 206, 30.09.2019

Hevişan Akdağ Sahra Kırmusaoğlu

https://doi.org/10.46373/hafebid.526525

Cited By: 1

Öz

Romatoid artrit (RA), genel popülasyonun yaklaşık %1’ini etkilediği düşünülen, bağ
dokusu hasarını hedef alan kronik bir otoimmün ve insanın bağışıklık sisteminin vücuttaki kendi sağlıklı hücreleriyle savaşması sonucunda ortaya çıkan bir hastalıktır.
Romatoid artritli hastalarda, bağ dokusu hasarının ilerlemesi, sakatlığa, hastaların
yaşam kalitesinin azalmasına ve mortaliteye sebep olmaktadır. RA’yı tamamen tedavi eden bir tedavi seçeneği henüz yoktur. RA’nın erken tanısı ve tedavisi ile hastaların %90’ının eklem hasarının ilerlemesi ya da hasar oluşumu yavaşlatılabilir.
Geleneksel tedavilerin yetersizliğinden dolayı, romatoid artrit tedavisinin etkili ve
spesifik bir biçimde gerçekleşmesi için güncel tedavilere ihtiyaç duyulmaktadır. Bu
derlemede, romatoid artrit tedavisinde uygulanan geleneksel tedaviler ve modern terapötik yaklaşımlar ele alınacaktır.

Anahtar Kelimeler

Romatoid artrit, Modern terapötik yaklaşımlar, Geleneksel tedaviler, Otoimmün hastalık

The Recent Approaches Applied in the Treatment of Rheumatoid Arthritis

Öz

Rheumatoid arthritis (RA) is a chronic autoimmune that is thought to affect about
1% of the general population, and is a disease caused by the human immune system
fighting its own healthy cells in the body. RA is a disease that emerges as a result of fighting of human immune system with its own healthy cells. In patients who have
rheumatoid arthritis, progression of connective tissue damage leads to disability,
decreased quality of life of patients, and mortality. There is not a treatment option
yet that treat RA completely. With early diagnosis and the treatment of RA, joint
damage progression or formation of damage of 90% of patients can be decelerated.
Due to the insufficiency of traditional treatments, up-to-date treatment options are
needed for effective and specific treatment of rheumatoid arthritis. In this review,
traditional treatments and modern therapeutic approaches applied in the treatment
of RA will be discussed.

Anahtar Kelimeler

Rheumatoid arthritis, Modern therapeutic approaches, Traditional treatments, Autoimmune disease

Kaynakça

• Hashemi, M., Atabaki, M.,Daneshvar , H., et al. Association of PTPN22 rs2476601 and EGFR rs17337023 Gene polymorphisms and rheumatoid arthritis in Zahedan, Southeast Iran. Int J Immunogenet. 40 (4), (2013), 299-305. DOI: https://doi.org/10.1111/iji.12038
• J, Becker., KL,Winthrop., Update on rheumatic manifestations of infectious diseases. Curr Opin Rheumatol. 22 (1), (2010), 72-7. DOI: 10.1097/BOR.0b013e328333b9f5.
• [http://www.who.int/chp/topics/rheumatic/en/ (Erişim tarihi:15 aralık 2018).
• B., S., Ma, T., Genovese, M., & Lane Smith, R. et al. Cox-2 Selective Inhibitors and Bone. International Journal of Immunopathology and Pharmacology, (2003), 201–205. DOI: https://doi.org/10.1177/039463200301600303
• Furst, DE., Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 26 (1), (1997), 21-27. DOI: https://doi.org/10.1016/S0049-0172(97)80049-2
• 2002 Update American College of Rheumatology Subcommitee on Rheumatoid Arthtitis Guidelines. Guidelines for the management of rheumatoid arthritis: Arthritis Rheum. 46 (2), (2002), 328-346. DOI: 10.1002/art.10148
• Quan, L.,Macromolecular Nanomedicine of Glucocorticoids for the Treatment of Rheumatoid Arthritis. J Nanomed Nanotechol. 4 (1), (2013) ,126. DOI: 10.4172/2157-7439.1000e126
• Kirwan, J., Boers, M., Low dose prednisolone for treatment of RA Annals of the Rheumatic Diseases. 63 (11), (2004), 1533-1534. DOI: http://ard.bmj.com/content/63/11/1533.
• Wendling, D., Wijdenes, J., Racadot, E., Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J. Rheumatol. 18 (3), (1991), 325–327. DOI: https://doi.org/10.1046/j.1365-2036.1996.59201000.x
• Van de, Putte., Atkins, C., Malaise, M., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous diseasemodifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63, (2004), 508–516. DOI: 10.1136/ard.2003.013052
• Jacobs, JWG., Everdingen, AAV., Verstappen, SMM., et al. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. Arthritis Rheum. 54 (5), (2006), 1422-1428. DOI: https://doi.org/10.1002/art.21809
• Smolen, JS., Aletaha, D., Koeller, M., New therapies for treatment of rheumatoid arthritis. Lancet. 370 (9602), (2007), 1861–1874. DOI: 10.1016/S0140-6736(07)60784-3
• Parmentier, J., Voss, J., Graff, C., et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatology. 2 (23), (2018), 1. DOI: https://doi.org/10.1186/s41927-018-0031-x
• Toussirot, EA., Oral tolerance in the treatment of rheumatoid arthritis. Curr Drug Targets Inflamm Allergy. 1 (1), (2002), 45-52. DOI: https://doi.org/10.2174/1568010023344850
• Gregoriadis, G., Drug entrapment in liposomes. FEBS Lett. 36 (3), (1973), 292–296. DOI: https://doi.org/10.1016/0014-5793(73)80394-1
• Arora, R., Kuhad, A., Kaur, I.P., et al. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant‐induced arthritis in rats. European Journal of Pharmacology. 19 (7), (2014), 940-952. DOI: https://doi.org/10.1002/ejp.620
• Allen,TM., Hansen, C., Martin, F., et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1066 (1), (1991), 29–36. DOI: http://dx.doi.org/10.1016/0005-2736(91)90246-5
• Samad, A., Sultana, Y., Aqil, M., Liposomal Drug Delivery Systems: an update review, Current drug delivery. 4 (4), (2007), 297-305. DOI: 0.2174/156720107782151269
• Wehling, P., Reinecke, J., Baltzer, A. W., et al. Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis. Human gene therapy, 20(2), (2009), 97-101. DOI: 10.1089/hum.2008.075
• Evans, C. H., Ghivizzani, S. C., & Robbins, P. D., Arthritis gene therapy's first death. Arthritis research & therapy.10 (3), (2008), 110. DOI: 10.1186/ar2411
• Scheller, E. L., & Krebsbach, P. H. Gene therapy: design and prospects for craniofacial regeneration. Journal of dental research.88 (7), (2009), 585-96. DOI: 10.1177/0022034509337480
• Mahmoudi, M., Sant, S., Wang, B., et al. Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy.Adv Drug Deliv Rev. 63 (1-2) ,(2011), 24-46. DOI: 10.1016/j.addr.2010.05